Want to see JP:4599 full AI Analyst Report?
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥169.00 - ¥368.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)651.53K
Market Cap
¥11.09B
Enterprise Value¥13.10K
Total Cash (Recent Filing)¥5.38B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Dec 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.69
Shares Outstanding62,681,200
10 Day Avg. Volume1,160,220
30 Day Avg. Volume651,526
Financial Highlights & Ratios
PEG Ratio2.05
Price to Book (P/B)3.26
Price to Sales (P/S)0.00
P/FCF Ratio-11.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.8
Revenue Forecast (FY)¥540.00M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of meaningful debt reduces leverage and interest-burden risk, giving StemRIM more flexibility than a similarly unprofitable company with heavy borrowing. This provides a modest financial buffer while management works to restore commercialization and cash generation.
Prior Revenue And Cash GenerationStemRIM previously produced substantial revenue alongside positive operating and free cash flow, showing that the business has at least once demonstrated commercial and cash-generation capacity. Although performance subsequently reversed, this history provides a basis for assessing potential recovery.
Compact WorkforceA workforce of 45 employees indicates a compact operating base, which may support focused execution and limit organizational complexity as the company advances its biotechnology activities. A smaller structure can also allow resources to be concentrated on priority development and commercialization efforts.
Bears Say
Zero Revenue And Expanding LossesThree consecutive years of zero reported revenue combined with losses near ¥2B demonstrate that StemRIM is not currently converting its activities into commercial income. Persistent unprofitability weakens earnings visibility, erodes capital, and increases dependence on future financing or business recovery.
Sustained Cash BurnSustained operating and free-cash-flow deficits indicate that the company is consuming cash rather than funding operations internally. Because the burn is broadly aligned with accounting losses, there appears to be limited cash-flow offset, creating ongoing funding and runway risk if losses persist.
Capital Erosion And Negative ReturnsDeclining equity and assets show that continuing losses are consuming the company’s capital base despite its low-debt position. Deeply negative returns on equity also indicate that shareholder resources are not currently producing returns, limiting financial resilience and future strategic flexibility.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥169.00 and its highest was ¥368.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥11.09B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Dec 16, 2026 which is in 84 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Sep 09, 2026. The company reported -¥7.12 earnings per share for the quarter.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥7.12 in its last earnings report. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―